Search Results - "James, Douglas E."

Population pharmacokinetics and pharmacodynamics of nasal glucagon in patients with type 1 or 2 diabetes by James, Douglas E., Shen, Tong, Geiser, Jeanne S., Garhyan, Parag, Chigutsa, Emmanuel

“…The objective was to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of glucagon after injectable or nasal administration and confirm the…”
Get full text

Dose Rationale of Nasal Glucagon in Japanese Pediatric Patients with Diabetes Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation by Nasu, Risa, James, Douglas E., Chigutsa, Emmanuel, Garhyan, Parag, Nagai, Yukiko

“…Background Nasal glucagon (NG) 3 mg is approved in Japan to treat hypoglycemia in pediatric patients with diabetes, but an NG clinical study has not been…”
Get full text

Limiting hospital resources for acute appendicitis in children: Lessons learned from the U.S. epicenter of the COVID-19 pandemic by Kvasnovsky, Charlotte L, Shi, Yan, Rich, Barrie S, Glick, Richard D, Soffer, Samuel Z, Lipskar, Aaron M, Dolgin, Stephen, Bagrodia, Naina, Hong, Andrew, Prince, Jose M, James, Douglas E, Sathya, Chethan

“…The COVID-19 pandemic resulted in the suspension of nonemergent surgeries throughout New York. Our tertiary care children’s hospital pivoted towards a brief…”
Get full text

The relative timing of exposure to phagocytosable particulates and to osteoclastogenic cytokines is critically important in the determination of myeloid cell fate by James, Douglas E, Nestor, Bryan J, Sculco, Thomas P, Ivashkiv, Lionel B, Ross, F Patrick, Goldring, Steven R, Purdue, P Edward

“…During granulomatous inflammatory reactions, myeloid cells can differentiate into activated phagocytic macrophages, wound-healing macrophages, foreign body…”
Get full text

Congenital mesoblastic nephroma with distant metastasis in a premature twin gestation by James, Douglas E, Sulkowski, Jason P, Smith, Michael C, Barone, Anthony, Parab, Santosh, Graziano, Joan, Velcek, Francisca T

“…Abstract Congenital mesoblastic nephroma (CMN) is a rare renal tumor of infancy. Here, we present a case of CMN presenting in a 29 week premature male in a…”
Get full text

Interleukin‐33 antibody failed to demonstrate benefit in a phase II, double‐blind, randomized, placebo‐controlled study in adult patients with moderate‐to‐severe atopic dermatitis by Laquer, Vivian, Parra, Viviana, Lacour, Jean‐Philippe, Takahashi, Hidetoshi, Knorr, Jack, Okragly, Angela J., James, Douglas E., Sims, Jonathan T., Chang, Ching‐Yun, Chao, Jeannie, Klekotka, Paul

Get full text

Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients by Shen, Tong, James, Douglas E., Krueger, Kathryn A.

“…ABSTRACT Purpose LY3015014 is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that binds to the catalytic domain of PCSK9 and reduce low-density…”
Get full text

The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans by May, Patrick C, Willis, Brian A, Lowe, Stephen L, Dean, Robert A, Monk, Scott A, Cocke, Patrick J, Audia, James E, Boggs, Leonard N, Borders, Anthony R, Brier, Richard A, Calligaro, David O, Day, Theresa A, Ereshefsky, Larry, Erickson, Jon A, Gevorkyan, Hykop, Gonzales, Celedon R, James, Douglas E, Jhee, Stanford S, Komjathy, Steven F, Li, Linglin, Lindstrom, Terry D, Mathes, Brian M, Martényi, Ferenc, Sheehan, Scott M, Stout, Stephanie L, Timm, David E, Vaught, Grant M, Watson, Brian M, Winneroski, Leonard L, Yang, Zhixiang, Mergott, Dustin J

“…BACE1 is a key protease controlling the formation of amyloid β, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease…”
Get full text

Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat by Willis, Brian A., Andersen, Scott W., Ayan‐Oshodi, Mosun, James, Douglas E., Liffick, Emily, Hillgren, Kathleen, Guo, Yingying, Monk, Scott A.

“…Lanabecestat is a human β‐site amyloid precursor protein‐cleaving enzyme 1 inhibitor in development to slow disease progression in patients with early…”
Get full text

Reply to letter to the editor regarding New York's COVID-19 shelter-in-place and acute appendicitis in children by Kvasnovsky, Charlotte L, Shi, Yan, Rich, Barrie, Glick, Richard D, Soffer, Samuel Z, Lipskar, Aaron M, Dolgin, Stephen, Bagrodia, Naina, Hong, Andrew, Prince, Jose M, James, Douglas E, Sathya, Chethan

Get full text

Reply to letter to the editor by Kvasnovsky, Charlotte L, Shi, Yan, Rich, Barrie S, Glick, Richard D, Soffer, Samuel Z, Lipskar, Aaron M, Dolgin, Stephen, Bagrodia, Naina, Hong, Andrew, Prince, Jose M, James, Douglas E, Sathya, Chethan

Get full text

Profile of an American Amateur Rugby Union Sevens Series by Lopez, Victor, Galano, Gregory J., Black, Christopher M., Gupta, Arun T., James, Douglas E., Kelleher, Kristen M., Allen, Answorth A.

“…Background: Rugby union will enter the Olympic arena as Rugby Sevens in 2016. Purpose: To investigate the injury rate, injury type, and nature of injuries…”
Get full text

Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P‐gp Substrate by Monk, Scott A., Kugler, Alan R., Andersen, Scott W., Ayan‐Oshodi, Mosun A., James, Douglas E., Mullen, Jamie, Zimmer, Jennifer A., Willis, Brian A.

“…Lanabecestat, a novel β‐site amyloid precursor protein–cleaving enzyme 1 inhibitor evaluated for Alzheimer treatment, inhibits P‐glycoprotein (P‐gp) activity…”
Get full text

Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species by Willis, Brian A., Lowe, Stephen L., Monk, Scott A., Cocke, Patrick J., Aluise, Christopher D., Boggs, Leonard N., Borders, Anthony R., Brier, Richard A., Dean, Robert A., Green, Steven J., James, Douglas E., Jhee, Stanford S., Lin, Qun, Lo, Albert C., May, Patrick C., Watson, Brian M., Winneroski, Leonard L., Yang, Zhixiang, Zimmer, Jennifer A., McKinzie, David L., Mergott, Dustin J.

“…Background: The development of beta-site amyloid-beta precursor protein cleaving enzyme (BACE) 1 inhibitors for the treatment of Alzheimer’s disease requires…”
Get full text

Venlafaxine for pathological crying after stroke by Smith, Amanda G, Montealegre-Orjuela, Mercedes, Douglas, James E, Jenkins, Elizabeth A

Get full text

Population Pharmacokinetics in Healthy Subjects and Hypercholesterolemia Patients by Shen, Tong, James, Douglas E, Krueger, Kathryn A

“…Purpose LY3015014 is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that binds to the catalytic domain of PCSK9 and reduce low-density lipoprotein…”
Get full text

Improving Clinical Competencies for the Surgical Clerkship by Shraga, Sarrina, Barrera, Kaylene, Klein, Michael J., Kohler, Casey, James, Douglas E., DiRaimo, Robert, Sugiyama, Gainosuke

Get full text

Sternoclavicular Injury - Rugby Union (15-players-a-side): 3533 June 3 10 20 AM - 10 40 AM by Lopez, Victor, Ma, Richard, James, Douglas E., Wilinski, Michael S., Allen, Answorth A.

Get full text

Sternoclavicular Injury - Rugby Union (15-players-a-side): 2346 Board #6 June 1 5 45 PM - 6 45 PM by Lopez, Victor, Ma, Richard, James, Douglas E., Wilinski, Michael S., Allen, Answorth A.

Get full text

P1‐039: LANABECESTAT DOES NOT AFFECT PHARMACOKINETICS OF THE BCRP SUBSTRATE ROSUVASTATIN by Monk, Scott A., Andersen, Scott W., Ayan-Oshodi, Mosun, Guo, Yingying, Hillgren, Kathleen M., James, Douglas E., Liffick, Emily, Willis, Brian A.

Get full text